直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

House Committee Approves Innovation Act With Changes to AIA Post-Grant Proceedings

June 17, 2015

Authored and Edited by C. Brandon Rash

On the heels of the Senate Judiciary Committee approving the PATENT Act, the House Judiciary Committee approved its own patent reform bill, known as the Innovation Act, on June 11, 2015. Several provisions in the Innovation Act impact AIA post-grant proceedings.

The Innovation Act includes several of the same changes regarding post-grant proceedings as the PATENT Act. For example, the Innovation Act changes the claim construction standard in AIA proceedings from the “broadest reasonable interpretation” standard to the Phillips standard used in district courts, and requires the USPTO to consider any prior district court constructions. The Act also allows the patent owner to submit new testimonial evidence with its preliminary response and allows the petitioner to file a reply to new issues raised in the preliminary response.

In IPRs and PGRs that result in a final written decision, the AIA estops petitioners from asserting grounds that the petitioner “raised or reasonably could have raised” during the proceeding in a later district court or ITC proceeding. The Innovation Act limits the estoppel in PGRs to the grounds petitioner “raised” in the PGR proceeding. The “raised or reasonably could have raised” estoppel would continue to apply in IPRs.

The Innovation Act also requires the petitioner to certify that (1) it does not own and will not acquire a financial instrument designed to hedge a drop in stock value as a result of the petition; and (2) it has not demanded a payment from the patent owner in exchange for a commitment not to file the petition, unless the petitioner has been sued for or charged with infringement of the patent.

Next, the Innovation Act sets forth certain PTAB institution decisions as precedential. In these decisions, the USPTO denied institution of IPRs under 35 U.S.C. § 325(d) based on the petition raising substantially the same prior art or arguments previously presented to the USPTO.

The AIA limits the scope of prior art in CBM review proceedings to § 102(a) art, which includes patents and printed publications that issued or published before the invention. The Innovation Act expands the scope of prior art to include § 102(e) prior art, which includes certain patents and application publications that issued or published after, but have an effective filing date before, the invention.

Lastly, the Innovation Act permits the USPTO to waive payment of the filing fee for CBM review proceedings.

Tags

claim construction, estoppel, Innovation Act, patent reform, prior art

Related Practices

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Copyright © 2015 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information. 

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Charitable

Bridges From School to Work Gala 2026

June 22, 2026

Washington, DC

Charitable

Banding Together 2026

June 18, 2026

Washington, DC

Conference

2026 Copyright Society Annual Meeting

June 14-16, 2026

Louisville

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP